erectile dysfunction	0	1.7759	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
foot problems	0	1.6525	1	Diabetic foot problems 1 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	
insulin delivery	0	1.6525	1	Insulin delivery 8 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	
kidney disease	1	1.6525	2	Diabetic kidney disease 2 For guidance on managing kidney disease in adults with type 2 diabetes, see the	NICE guideline on chronic kidney disease in adults.	
standard-release metformin	0	1.6525	1	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
ace inhibitor	0	1.6366	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
autonomic neuropathy	0	1.5235	4	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Last updated May 2017 0 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
3–6 months	0	1.5204	2	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
details medicines	0	1.5204	0	
dose titration	0	1.5204	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
heart failure	0	1.5204	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
minute 3m2	0	1.5204	2	Last updated May 2017 2 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 3m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
ml minute	0	1.5204	2	Last updated May 2017 2 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 3m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
product characteristics	0	1.5204	2	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
risk factors	0	1.5204	2	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
blood pressure	0	1.4586	4	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
mmol mol	0	1.329	4	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
healthcare products	0	1.3231	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (	
products regulatory	0	1.3231	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (	
regulatory agency	0	1.3231	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (	
angiotensin ii-receptor	0	1.3119	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
ii-receptor antagonist	0	1.3119	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
glp-1 mimetic	0	1.2665	2	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Last updated May 2017 1 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
family members	0	1.2651	3	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
caribbean family	0	1.2639	2	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
family origin	0	1.2639	2	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
acute intercurrent	0	1.2263	1	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
advise adults	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
antiplatelet therapy	0	1.2263	1	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	
bladder-emptying problems	0	1.2263	1	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
care advice	0	1.2263	1	Last updated May 2017 1 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
class level	0	1.2263	1	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 7 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	
consultant-led multidisciplinary	0	1.2263	1	Last updated May 2017 1 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
contributory sympathetic	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
diabetic peripheral	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
differential diagnosis	0	1.2263	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
disease offer	0	1.2263	0	
energy intake	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
excess energy	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
first-line therapy	0	1.2263	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
generic calcium-channel	0	1.2263	1	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
hyperglycaemia review	0	1.2263	0	
independent assessors	0	1.2263	1	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	
intercurrent illness	0	1.2263	1	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
intolerance review	0	1.2263	0	
limited substitution	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
meal plan	0	1.2263	2	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
measure blood	0	1.2263	1	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	
multidisciplinary team	0	1.2263	1	Last updated May 2017 1 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
nervous system	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
neuropathic pain	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
neuropathy symptoms	0	1.2263	1	Last updated May 2017 0 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
nocturnal diarrhoea	0	1.2263	1	Last updated May 2017 0 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
ongoing support	0	1.2263	1	Last updated May 2017 1 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
painful diabetic	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
peripheral neuropathy	0	1.2263	1	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
pressure control	0	1.2263	1	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	
preventive lifestyle	0	1.2263	1	Offer and reinforce preventive lifestyle advice.	
renal disease	0	1.2263	1	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	
rescue therapy	0	1.2263	1	Rescue therapy at any phase of treatment 8 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 2– 4) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	
severe vomiting	0	1.2263	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
specialist care	0	1.2263	1	Last updated May 2017 1 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
specialist services	0	1.2263	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
specific interventions	0	1.2263	1	Last updated May 2017 0 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
sucrose-containing foods	0	1.2263	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
sympathetic nervous	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
system damage	0	1.2263	1	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
thiazide-related diuretic	0	1.2263	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
unexplained bladder-emptying	0	1.2263	1	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
visual impairment	0	1.2263	1	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	
diabetic foot	0	1.2202	1	Diabetic foot problems 1 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	
review treatment	0	1.2083	3	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Review treatment as necessary. 6 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	Rescue therapy at any phase of treatment 8 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 2– 4) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	
cardiovascular disease	0	1.1987	3	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
body weight	0	1.1916	2	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	
initial body	0	1.1916	2	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	
dpp-4 inhibitor	0	1.1857	2	First intensification of drug treatment 5 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 6 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
gastrointestinal side	0	1.1551	1	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
calcium-channel blocker	0	1.1491	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
bariatric surgery	0	1.1356	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
recent-onset type	0	1.1356	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
triple therapy	0	1.1241	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
5–10percent individualise	0	1.1225	0	
alcohol intake	0	1.1225	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
balanced eating	0	1.1225	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
emphasise advice	0	1.1225	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
general population	1	1.1225	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
healthy balanced	0	1.1225	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
individualise recommendations	0	1.1225	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
insulin secretagogue	0	1.1225	1	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	
loss target	0	1.1225	1	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
meal patterns	0	1.1225	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
hba1c target	0	1.1089	3	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
side effects	0	1.1071	2	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
dipeptidyl peptidase-4	0	1.1041	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 7 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
beneficial metabolic	0	1.0636	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
metabolic response	0	1.0636	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
mimetic therapy	0	1.0636	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
mol percent	0	1.0636	0	
adults nice	0	1.0595	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
angiotensin-converting enzyme	0	1.0595	1	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
blood type	0	1.0595	0	
generic angiotensin-converting	0	1.0595	1	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
guideline cg127	0	1.0595	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
inhibitor african	0	1.0595	0	
interventions section	0	1.0595	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
lifestyle interventions	0	1.0595	1	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	
myocardial infarction	1	1.0275	1	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
secondary prevention	0	1.0275	1	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
initial drug	0	1.0118	3	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	First intensification of drug treatment 5 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 6 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	
eye screening	0	1.0111	3	Eye disease 7 On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Last updated May 2017 8 Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome. 9 Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
antihypertensive drug	0	1.0088	4	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
glucagon-like peptide-1	1	0.9999	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 7 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
drug treatments	0	0.9895	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
orthostatic hypotension	0	0.9895	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
tricyclic drugs	0	0.9895	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
unexplained diarrhoea	0	0.9895	1	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	
hba1c targets	0	0.9807	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
low hba1c	0	0.9807	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
renal function	0	0.9807	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
sudden weight	0	0.9807	1	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
alternative diagnoses	0	0.9713	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
antiemetic therapy	0	0.9713	1	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	
erratic blood	0	0.9713	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
strong evidence	0	0.9713	1	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	
unexplained gastric	0	0.9713	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
dual therapy	0	0.9613	3	First intensification of drug treatment 5 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 6 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	
diabetes care	0	0.9483	1	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
long-term interventions	0	0.9483	1	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
personal preferences	0	0.9483	1	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
first-line antihypertensive	0	0.9368	2	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
weight loss	0	0.9331	4	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	
glucose levels	0	0.9325	4	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Review treatment as necessary. 6 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
care pathway	0	0.9318	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
diabetes healthcare	0	0.9318	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
healthcare team	0	0.9318	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
local programmes	0	0.9318	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
nph insulin	1	0.9257	2	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
hba1c levels	0	0.9248	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
hba1c level	0	0.9224	7	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
patient-education programme	0	0.9184	2	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
glucose 2	1	0.9182	1	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
licensing agency	0	0.9182	1	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
vehicle licensing	0	0.9182	1	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
current medical	0	0.8917	2	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
glance guide	0	0.8917	2	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
medical standards	0	0.8917	2	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
agency mhra	0	0.8825	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
clinical circumstances	0	0.8825	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
drug treatment(s)	0	0.8825	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
individual clinical	0	0.8825	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
individual preferences	0	0.8825	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
licensed indications	0	0.8825	1	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
insulin-based treatment	0	0.8724	3	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
oral drugs	0	0.8724	2	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	
hypoglycaemic episodes	0	0.8702	1	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
intravenous corticosteroids	0	0.8702	1	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
oral medication	0	0.8702	1	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
short-term self-monitoring	0	0.8702	1	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
suspected hypoglycaemia	0	0.8702	1	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
lifestyle advice	0	0.8604	4	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	
nice guidelines	0	0.8519	2	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
mhra guidance	0	0.8179	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
3–6-monthly intervals	0	0.8058	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
6-monthly intervals	0	0.8058	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
hba1c measurement	0	0.8058	1	HbA1c measurement and targets	
measure hba1c	0	0.8058	2	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Use methods to measure HbA1c that have been calibrated according to	
therapy 6-monthly	0	0.8058	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
unchanging therapy	0	0.8058	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
continued benefit	0	0.8027	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
glucose results	0	0.8027	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
self-monitoring skills	0	0.8027	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
structured assessment	0	0.8027	1	Review treatment as necessary. 6 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	
active insulin	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
control support	0	0.7989	1	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
dietary understanding	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
dvla guidance	0	0.7989	1	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
hypoglycaemia management	0	0.7989	1	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
injection sites	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
injection technique	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin dose	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
insulin-based treatments	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
levels dietary	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
plasma glucose	0	0.7989	1	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
repeated injections	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
self-monitoring dose	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
starting insulin	0	0.7989	3	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
structured programme	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
support self-monitoring	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
telephone support	0	0.7989	1	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
understanding dvla	0	0.7989	0	
single drug	0	0.7973	2	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
failure type	0	0.7961	0	
sodium–glucose cotransporter	0	0.7961	1	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	
annual reinforcement	0	0.7935	1	Last updated May 2017 annual reinforcement and review	
education programme	0	0.7935	3	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
review ensure	0	0.7935	0	
self-manage diabetes	0	0.7935	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
specific aims	0	0.7935	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
structured education	0	0.7935	2	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	
phosphodiesterase-5 inhibitor	0	0.7864	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
problematic erectile	0	0.7864	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
diabetes type	0	0.784	0	
estimated glomerular	0	0.784	1	Last updated May 2017 2 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 3m2:	
filtration rate	0	0.784	1	Last updated May 2017 2 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 3m2:	
glomerular filtration	0	0.784	1	Last updated May 2017 2 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 3m2:	
kidney function	0	0.784	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
prescribe metformin	0	0.784	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
sudden deterioration	0	0.784	1	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
insulin therapy	0	0.7787	4	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Insulin-based treatments 2 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Review the continued need for other blood glucose lowering therapies . 4 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
drug treatment	0	0.7445	12	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 7 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute 3m2. 3 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 4 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	First intensification of drug treatment 5 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 6 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
life expectancy	0	0.7444	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
licensed non-metformin-based	0	0.7422	2	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
non-metformin-based combination	0	0.7422	2	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
eye disease	0	0.7204	1	Eye disease 7 On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
local eye	0	0.7204	1	Eye disease 7 On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
screening service	0	0.7204	1	Eye disease 7 On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
screening systems	0	0.7204	1	Last updated May 2017 8 Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome. 9 Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	
service type	0	0.7204	0	
effective treatment	0	0.7088	1	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
exceptional circumstances	0	0.7088	1	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
informed discussion	0	0.7067	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
renal deterioration	0	0.7067	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 0 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 2 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	
blood glucose	0	0.7046	12	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Self-monitoring of blood glucose 2 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 3 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Review treatment as necessary. 6 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	Rescue therapy at any phase of treatment 8 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 2– 4) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Review the continued need for other blood glucose lowering therapies . 4 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
national screening	0	0.7026	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
screening type	0	0.7026	0	
insulin detemir	0	0.7002	2	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
insulin glargine	0	0.7002	2	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
glucose control	0	0.6973	5	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Rescue therapy at any phase of treatment 8 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 2– 4) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
nice guideline	0	0.6702	9	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss. 1 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy. 4 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 5 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	Insulin delivery 8 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Diabetic foot problems 1 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	
chronic kidney	0	0.6675	1	NICE guideline on chronic kidney disease in adults.	
diabetic kidney	0	0.6675	1	Diabetic kidney disease 2 For guidance on managing kidney disease in adults with type 2 diabetes, see the	
acquisition cost	0	0.6654	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
delivery section	0	0.655	1	Insulin delivery 8 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	
acuity testing	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
arrange emergency	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
arrange rapid	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
digital retinal	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
emergency review	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
haemorrhage retinal	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
iridis pre-retinal	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
perform visual	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
photography programme	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
quality-assured digital	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
rapid review	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
retinal detachment	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
retinal photography	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
routine part	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
routine review	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
rubeosis iridis	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
screening programmes	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
sudden loss	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
trained staff	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
vessel formation	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
vision rubeosis	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
visual acuity	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
vitreous haemorrhage	0	0.6465	1	Discussions should include precautions for driving. 0 Use a quality-assured digital retinal photography programme using appropriately trained staff. 1 Perform visual acuity testing as a routine part of eye screening programmes. 2 Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist. 3 Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment. 4 Arrange rapid review by an ophthalmologist for new vessel formation. 5 Refer to an ophthalmologist in accordance with the National Screening	
cerebrovascular damage	0	0.6396	1	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
pressure measurements	0	0.6396	1	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
repeat blood	0	0.6396	1	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	
modified-release metformin	0	0.6069	1	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
offer standard-release	0	0.6069	1	Initial drug treatment 9 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 0 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
human insulin	0	0.5916	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
insulin preparations	0	0.5916	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
insulin types	0	0.5916	1	Review the continued need for other blood glucose lowering therapies . 4 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
short-acting human	0	0.5916	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
short-acting insulin	0	0.5916	2	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
start insulin	0	0.5916	1	Review the continued need for other blood glucose lowering therapies . 4 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
carbohydrate content	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
excess weight	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
harm reduction	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
health services	1	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
meal planning	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
mental health	1	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
physical activity	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
planning system	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
smoking services	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
weight gain	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
weight management	0	0.5859	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 0 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
combination therapy	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
ethnic groups	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
kg m2	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
kg m2and	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
medical problems	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
minority ethnic	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
obesity-related comorbidities	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
occupational implications	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
oral drug	0	0.5738	2	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months). 0 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 6) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 2– 4).	
significant obesity-related	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
significant occupational	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
specific psychological	0	0.5738	1	Second intensification of drug treatment 7 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 5) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 2– 4). 8 If triple therapy with metformin and 2 other oral drugs (see recommendation 7) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 9 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	
glucose measurements	0	0.568	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
individual hba1c	0	0.568	1	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
investigate unexplained	0	0.568	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
involve adults	0	0.568	1	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
measurements involve	0	0.568	0	
offer lifestyle	0	0.568	1	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	
target offer	0	0.568	0	
unexplained discrepancies	0	0.568	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
healthcare professional	0	0.5332	2	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 3 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
case-by-case basis	0	0.4801	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
high risk	0	0.4801	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
intensive management	0	0.4801	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
risk-reduction benefits	0	0.4801	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
significant comorbidities	0	0.4801	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
tight blood	0	0.4801	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 0 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
monitor adults	0	0.4708	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
significant hypoglycaemia	0	0.4708	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
annual review	0	0.4078	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
contributory factors	0	0.4078	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
offer men	0	0.4078	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
psychological management	0	0.4078	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
treatment options	0	0.4078	1	Erectile dysfunction 3 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 4 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 5 Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications. 6 Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
insulin analogues	0	0.405	2	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
conditions notice-of-rights	0	0.392	21	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
target hba1c	0	0.3421	2	Consider relaxing the target HbA1c level (see recommendations and )	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
basal bolus	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
basal insulin	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
biphasic insulin	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
bolus regimen	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
daily injections	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
insulin injections	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
insulin preparation	0	0.2376	2	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 5 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
insulin regimen	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
pre-mixed biphasic	0	0.2376	1	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 6 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 7 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
